Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.90 -0.05 (-5.54%)
As of: Oct 1, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2010 - 2026)

Updated

Lineage Cell Therapeutics (LCTX) reported Depreciation & Amortization (CF) of $187,000 for Q2 2026, up 9.4% from $171,000 a year earlier but down 0.5% from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Lineage Cell Therapeutics' Depreciation & Amortization (CF) came in at $739,000, up 17.9% year-over-year; for FY2025, it came in at $699,000, up 19.1% from FY2024.

  • Depreciation & Amortization (CF) has a five-year compound annual growth rate of -3.2% (FY2020 to FY2025).
  • By year, Depreciation & Amortization (CF) came in at $587,000 in FY2024 (+4.4%), $562,000 in FY2023 (-3.4%), $582,000 in FY2022 (-12.2%) and $663,000 in FY2021 (-19.4%).
  • Five-year quarterly Depreciation & Amortization (CF) spans a low of $138,000 in Q1 2023 and a high of $188,000 in Q1 2026.
  • Year over year, Depreciation & Amortization (CF) has now increased in each of the last seven quarters, with growth averaging 13.2% over the last eight quarters.
  • The high point for year-over-year Depreciation & Amortization (CF) in five years was Q3 2025 (growth of 26.2%); the low point was Q4 2021 (a decline of 20.5%).
  • Per Business Quant data, the three quarters before Q2 2026 came in at $188,000 (Q1 2026), $186,000 (Q4 2025) and $178,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.96 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 194.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.93 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 98.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 56.50 Mn
10 Lineage Cell Therapeutics 240.26 Mn 38.67 Mn - 187,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 187,000.00
Mar 31, 2026 188,000.00
Dec 31, 2025 186,000.00
Sep 30, 2025 178,000.00
Jun 30, 2025 171,000.00
Mar 31, 2025 164,000.00
Dec 31, 2024 151,000.00
Sep 30, 2024 141,000.00
Jun 30, 2024 142,000.00
Mar 31, 2024 153,000.00
Dec 31, 2023 143,000.00
Sep 30, 2023 143,000.00
Jun 30, 2023 138,000.00
Mar 31, 2023 138,000.00
Dec 31, 2022 141,000.00
Sep 30, 2022 145,000.00
Jun 30, 2022 146,000.00
Mar 31, 2022 150,000.00
Dec 31, 2021 159,000.00
Sep 30, 2021 166,000.00
API Access

Lineage Cell Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=LCTX&period=max&api_key=YOUR_API_KEY